リコンビナントタンパク質＿精製したリコンビナントタンパク質 » リコンビナント成長因子 » EPO, Human
EPO, Human

Biological Activity
EPO-alfa, Human (Cat. No. Z02975) stimulates cell proliferation of TF-1 cells. The ED50 for this effect is less than 1ng/mL.

EPO, Human

Erythropoietin (EPO), a glycoprotein produced primarily by the kidney, is the principal factor that regulates erythropoiesis by stimulating the proliferation and differentiation of erythroid progenitor cells. The production of EPO by kidney cells is increased in response to hypoxia or anemia. Recombinant EPO has been approved for the treatment of anemia associated with chronic renal failure as well as for anemia of AZT treated AIDS patients.The cDNAs for EPO have been cloned from human, mouse, canine, etc. The mature proteins from the various species are highly conserved, exhibiting greater than 80% sequence identity at the amino acid level. Human EPO cDNA encodes a 193 amino acid residue precursor protein that is processed to yield a 165 amino acid residue mature protein. EPO contains one O-linked and three N-linked glycosylation sites. Glycosylation of EPO is required for EPO biological activities in vivo. EPO exhibits structural as well as amino sequence identity to the amino terminal 153 amino acid region of thrombopoietin.
Z02975
¥10,875.00

Ask us a question
Product Introduction
Species Human
Protein Construction
EPO (Ala28-Arg193)
Accession # P01588
Purity > 95% as analyzed by SDS-PAGE
> 95% as analyzed by HPLC
Endotoxin Level < 0.2 EU/μg of protein by gel clotting method
Biological Activity ED50 < 1.0 ng/ml, measured in a cell proliferation assay using TF-1 human erythroleukemic cells, corresponding to a specific activity of > 1.0 × 106 units/mg
Expression System CHO
Theoretical Molecular Weight 21 kDa
Apparent Molecular Weight 26~36 kDa, on SDS-PAGE under reducing conditions.
Formulation Lyophilized after extensive dialysis against PBS.
Reconstitution It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH₂O or PBS up to 100 μg/ml.
Storage & Stability Upon receiving, this product remains stable for up to 6 months at lower than -70°C. Upon reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at -20°C. For long term storage it is recommended that a carrier protein (example 0.1% BSA) be added. Avoid repeated freeze-thaw cycles.

Examples
  • EPO, Human
    • EPO, Human

    Biological Activity
    EPO-alfa, Human (Cat. No. Z02975) stimulates cell proliferation of TF-1 cells. The ED50 for this effect is less than 1ng/mL.


Background
Target Background Erythropoietin (EPO), a glycoprotein produced primarily by the kidney, is the principal factor that regulates erythropoiesis by stimulating the proliferation and differentiation of erythroid progenitor cells. The production of EPO by kidney cells is increased in response to hypoxia or anemia. Recombinant EPO has been approved for the treatment of anemia associated with chronic renal failure as well as for anemia of AZT treated AIDS patients.The cDNAs for EPO have been cloned from human, mouse, canine, etc. The mature proteins from the various species are highly conserved, exhibiting greater than 80% sequence identity at the amino acid level. Human EPO cDNA encodes a 193 amino acid residue precursor protein that is processed to yield a 165 amino acid residue mature protein. EPO contains one O-linked and three N-linked glycosylation sites. Glycosylation of EPO is required for EPO biological activities in vivo. EPO exhibits structural as well as amino sequence identity to the amino terminal 153 amino acid region of thrombopoietin.
Synonyms EPO-alpha; EPO alpha; EPO

For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.